Table 6.

Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on pulse wave velocity (PWV), augmentation index (AI), central diastolic and systolic blood pressure (CBDP and CSBP) in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

	Prior to L-NMMA infusion (at 70 min)	During L-NMMA infusion (at 130 min)
PWV(m/s)
Placebo	7.5 ± 1.1	8.0 ± 1.3*
Tolvaptan 60 mg	7.6 ± 1.3	8.2 ± 1.4***
p (paired t-test, between)	0.598	0.501
AI (n = 16)
Placebo	21.1 ± 7.8	23.5 ± 7.3*
Tolvaptan 60 mg	21.1 ± 8.9	21.9 ± 9.1
p (paired t-test, between)	0.949	0.130
CSBP
Placebo	132 ± 11	144 ± 18***
Tolvaptan 60 mg	128 ± 9	139 ± 16***
p (paired t-test, between)	0.084	0.124
CDBP (n = 17)
Placebo	85 ± 9	93 ± 10***
Tolvaptan 60 mg	83 ± 8	88 ± 9***
p (paired t-test, between)	0.142	0.004

Data are given as mean ± SD. Paired t-test (*) was performed for comparison of means during L-NMMA infusion vs prior to L-NMMA infusion. Paired t-test was also used for comparison between tolvaptan and placebo treatment prior to L-NMMA infusion (at 70 min) and during L-NMMA infusion (at 130 min)

*p < 0.05; ***p < 0.0001